Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection

Transplantation

Volumn 69, Issue 12, 2000, Pages 2573-2580

  Reyes, Jorge ^a,b   Jain, Ashok ^a   Mazariegos, George ^a   Kashyap, Randeep ^a   Green, Mike ^a   Iurlano, Kathy ^a   Fung, John ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; PREDNISONE; TACROLIMUS;

ADOLESCENT; ARTICLE; CHRONIC DISEASE; DRUG CHOICE; DRUG EFFECT; FOLLOW UP; GRAFT REJECTION; HUMAN; LIVER FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034720765     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200006270-00017     Document Type: Article

References (30)

1. Goto S, Kamada N, Kim YI, Kobayashi M. Induction of immunosuppressive activity by splenic macrophages in liver-grafted rats. Transplant Proc 1991; 23 (3): 2017.
2. Fung JJ, Todo S, Jain A, et al. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc 1990; 22 (1): 6.
3. Fung JJ, Todo S, Tzakis A, et al. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc 1991; 23 (1 Pt 1): 14.
4. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2 (8670): 1000.
5. Demetris AJ, Fung JJ, Todo S, et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy - a clinicopathologic study of 96 patients. Transplantation 1992; 53 (5): 1056.
6. Klintmalm GB, Goldstein R, Gonwa T, et al. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transplant Proc 1993; 25 (1 Pt 1): 641.
7. D'Alessandro AM, Kalayoglu M, Pirsch JD, et al. FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. Transplant Proc 1991; 23 (6): 2987.
8. Lewis WD, Jenkins RL, Burke PA, et al. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection. Transplant Proc 1991; 23 (6): 2989.
9. Shaw BW Jr, Markin R, Stratta R, Langnas A, Donovan J, Sorrell M. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. Transplant Proc 1991; 23 (6): 2994.
10. Jost U, Winkler M, Ringe B, Rodeck B, Pichlmayr R. FK 506 treatment of intractable rejection after liver transplantation. Transplant Proc 1993; 25 (4): 2686.
11. McDiarmid SV, Klintmalm GB, Busuttil RW. FK506 conversion for intractable rejection of the liver allograft. Transpl Int 1993; 6 (6): 305.
12. Reding R, Wallemacq PE, Lamy ME, et al. Conversion from cyclosporine to FK506 for salvage of immunocompromised pé diatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children. Transplantation 1994; 57 (1): 93.
13. Sher LS, Cosenza CA, Michel J, et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation: a report of the U.S. Multicenter Liver Study Group. Transplantation 1997; 64 (2): 258.
14. Sokol RJ, Stall C. Anthropometric evaluation of children with chronic liver disease. Am J Clin Nutr 1990; 52 (2): 203.
15. Hamill PV, Drizd TA, Johnson CL, Reed RB, Roche AF, Moore WM. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr 1979; 32 (3): 607.
16. Rucay P, Samuel D, Farges O, Reynes M, Bismuth H. FK 506 as treatment of late acute rejection in liver transplant patients. Transplant Proc 1995; 27 (1): 1105.
17. Demetris AJ, Fung JJ, Todo S, et al. FK 506 used as rescue therapy for human liver allograft recipients. Transplant Proc 1991; 23 (6): 3005.
18. Felser I, Wagner S, Depee J, et al. Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. Transplant Proc 1991; 23 (6): 3032.
19. Tzakis AG, Reyes J, Todo S, et al. FK 506 versus cyclosporine in pediatric liver transplantation. Transplant Proc 1991; 23 (6): 3010.
20. Tzakis AG, Reyes J, Todo S, et al. Two-year experience with FK 506 in pediatric patients. Transplant Proc 1993; 25 (1 Pt 1): 619.
21. Venkataramanan R, Jain A, Warty VW, et al. Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc 1991; 23 (1 Pt 2): 931.
22. Jain AB, Fung JJ, Tzakis AG, et al. Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatrie orthotopic liver transplant patients. Transplant Proc 1991; 23 (6): 2763.
23. Jain AB, Venkataramanan R, Cadoff E, et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc 1990; 22 (1): 57.
24. McDiarmid SV, Wallace P, Vargas J, Ament ME, Busuttil RW. The treatment of intractable rejection with tacrolimus (FK506) in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr 1995; 20 (3): 291.
25. Egawa H, Esquivel CO, So SK, Cox K, Concepcion W, Lawrence L. FK506 conversion therapy in pediatric liver transplantation. Transplantation 1994; 57 (8): 1169.
26. Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59 (4): 524.
27. Jain AB, Reyes J, Mazariegos G, et al. Incidence of post transplant lymphoproliferative disorder in adults and children; consecutive 1000 primary liver transplantation under tacrolimus. Tranplantation 1999; 67 (7): S246 (Abstr).
28. Jara P, Robledo MJ, Frauca E, et al. Tacrolimus for steroid-resistant liver rejection in children. Transpl Int 1998; 11 (Suppl 1): S275.
29. Cao S, Cox KL, Berquist W, et al. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus. Pediatr Transplant 1999; 3(1): 22.
30. Jain AB RJ, Kashyap R et al. What have we learned about primary liver transplantation under tacrolimus immunosup-pression? Long term follow-up of the first 1000 patients. Ann Surg 1999; 230 (3): 441.